IGC Pharma (FRA:IGS1) Cash-to-Debt : 3.65 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. IGC Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.65.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, IGC Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for IGC Pharma's Cash-to-Debt or its related term are showing as below:

FRA:IGS1' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 3.41 Max: 512.2
Current: 3.66

During the past 13 years, IGC Pharma's highest Cash to Debt Ratio was 512.20. The lowest was 0.15. And the median was 3.41.

FRA:IGS1's Cash-to-Debt is ranked worse than
59.41% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs FRA:IGS1: 3.66

IGC Pharma Cash-to-Debt Historical Data

The historical data trend for IGC Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

IGC Pharma Cash-to-Debt Chart

IGC Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

515.11

23.07

14.86

17.21

6.97

IGC Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															9.82	6.97	4.36	7.52	3.65

Competitive Comparison of IGC Pharma's Cash-to-Debt

For the Biotechnology subindustry, IGC Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Cash-to-Debt falls into.

IGC Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

IGC Pharma's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.129	/	(0.124	+	0.325)
	=	6.97

IGC Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.264	/	(0.114	+	0.232)
	=	3.65

IGC Pharma (FRA:IGS1) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

IGC Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (FRA:IGS1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma (FRA:IGS1) Headlines

No Headlines